Furestem-CD is under clinical development by Kangstem Biotech and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Furestem-CD’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Furestem-CD overview
Furestem-CD (umbilical cord blood-derived mesenchymal stem cells) is under development for the treatment of moderate to severe Crohn’s disease. The stem cell therapy is administered through intravenous and subcutaneous injection. It consists of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) which are derived from immature new born cells and has the property of self-proliferation, immuno-modulation and pluripotency.
It was also under development for the treatment of plaque-type psoriasis.
Kangstem Biotech overview
Kangstem Biotech is a biopharmaceutical company. It develops stem cell therapeutic products stem cell therapy products, stem cell culture media products and umbilical cord blood-derived stem cell conditioned media products. The company’s products are used for the treatment. Kangstem Biotech’s stem cell therapy products include Furestem-AD for treating subacute and chronic atopic dermatitis, Furestem-RA for treating rheumatoid arthritis and Furestem-CD for treating active Crohn’s disease. It offers umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors. KangStem Biotech also provides stem cell culture media comprising KSB-3 kit, a medium for culturing the human mesenchymal stem cell. KangStem Biotech is headquartered in Seoul, South Korea.
For a complete picture of Furestem-CD’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
